Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | NEK2 | P51955 | 4/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277411 | 0.87 | MAPK13 (0.47) | MAPK13MAPK14 | |
| SCHEMBL3279744 | 0.77 | PDK2 (0.46) | HSD11B1MAPK13FLT3SCN9AMAPK14 | |
| SCHEMBL3277807 | 0.74 | MAPK13 (0.34) | MAPK13NEK2MAPK14 | |
| SCHEMBL380772 | 0.74 | MAPK13 (0.76) | MAPK13MAPK14 | |
| SCHEMBL3278458 | 0.73 | IMPDH2 (0.36) | MAPK13MAPK14 | |
| SCHEMBL379993 | 0.71 | MAPK13 (0.79) | MAPK13MAPK14 | |
| SCHEMBL8337857 | 0.66 | SCN9A (0.49) | SCN9A | |
| SCHEMBL7120106 | 0.66 | IKBKB (0.66) | — | |
| SCHEMBL6173688 | 0.66 | PARP1 (0.53) | HSD11B1SCN9A | |
| SCHEMBL27635469 | 0.65 | BCAT2 (0.62) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | MAPK1, MAP3K1, MAP3K7 | HSD11B1 2370/4885MAPK13 37/4885FLT3 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.